Phase II/III study of SM-88 in patients with metastatic pancreatic cancer.

Vincent Chung,Sant P. Chawla,Huan Dong,Semmie Kim,Ronald L. Korn,Kian-Huat Lim,Marcus Smith Noel,Anne M. Noonan,Paul E. Oberstein,Allyson J. Ocean,Shubham Pant,Vincent J. Picozzi,Philip A. Philip,Alexander S. Rosemurgy,Benjamin R. Tan,Andrea Wang-Gillam,Steve Wong,Giuseppe Del Priore

Phase II/III study of SM-88 in patients with metastatic pancreatic cancer.

2021

Vincent Chung
Sant P. Chawla
Huan Dong
Semmie Kim
Ronald L. Korn
Kian-Huat Lim
Marcus Smith Noel
Anne M. Noonan
Paul E. Oberstein
Allyson J. Ocean
Shubham Pant
Vincent J. Picozzi
Philip A. Philip
Alexander S. Rosemurgy
Benjamin R. Tan
Andrea Wang-Gillam
Steve Wong
Giuseppe Del Priore

437Background: SM-88 (racemetyrosine, Tyme Inc) is a dysfunctional tyrosine derivative used with MPS (methoxsalen 10mg, phenytoin 50mg and sirolimus 0.5mg). SM-88 was well tolerated with improvemen...

Keywords:

Phenytoin
Tyrosine
Cancer research
in patient
Methoxsalen
Sirolimus
Metastatic pancreatic cancer
Medicine

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations